L2P Research® Labs Continues unparalleled Growth as the Premier Minority-Owned Preclinical Research Lab in the U.S.
L2P Research Labs, a leading preclinical CRO, today announced its annual research accomplishments.
Dr. Suresh Anaganti, Chief Executive Officer of L2P Research Labs, shared contribution to preclinical data published in Cell Reports.
Link: https://www.cell.com/cell-reports/pdf/S2211-1247(21)01308-5.pdf
In addition to prestigious Cell Reports, L2P also announces its contribution to research work published in Sciences advances.
Link: https://www.science.org/doi/epdf/10.1126/sciadv.abi7511
As a Contract Research Laboratory specialized in Immune oncology, we are happy to share that our Renal carcinoma tumor model has been used to study Alphataxin, a small molecule drug that elevates tumor infiltration of CD4+ T- cells.
Link: https://www.frontiersin.org/articles/10.3389/fonc.2021.739080/full
L2P Research Labs brings unique capabilities and solid reputation in providing Preclinical Research services. Recently, L2P added 5,000 SFT GLP-compliant testing facility in Long Island, focused on providing Bioanalytical services.
About L2P Research Labs
L2P Research is a Pennsylvania based Research organization that provides integrated R&D support in all the key areas of pharmaceutical development. With a large worldwide customer base, L2P provides a complete array of research services as required for Investigational New Drug Applications (IND).
View source version on businesswire.com: https://www.businesswire.com/news/home/20220819005274/en/
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
